What is BPC-157 nasal spray?
BPC-157 is a synthetic 15-amino-acid peptide based on a partial sequence found in human gastric juice. It is an unapproved compound: it is not FDA-approved, has no USP monograph, and is not a component of any approved drug. It is sold as a "research chemical," usually labeled "not for human consumption" or "research use only." A US Department of Defense supplement-safety resource describes it plainly as "an unapproved drug" that "cannot be legally prescribed or sold over the counter."
A BPC-157 "nasal spray" is simply that same research-grade peptide put into a liquid intended to be sprayed into the nose rather than injected. The same DoD resource confirms these products are marketed to be taken "by mouth, injection, or nasal spray." The nasal version is promoted online for "cognitive," "neurological," or "systemic" benefits, on the theory that the nose offers a direct path toward the brain and an easier alternative to injecting. It is important to be precise from the start: that theory is the marketing pitch, not a finding from human research.
This page is not a how-to and does not provide a dose. It exists because "BPC-157 nasal spray dosage" is a question people type in — and the honest, evidence-based answer to it is mostly about what is *not* known.
Is there an official intranasal dose?
No. There is no official, standard, or approved intranasal dose of BPC-157 — and there is no approved dose by any other route either. Because BPC-157 is not an approved medicine anywhere in the world, no regulator has reviewed it, no prescribing label exists, and no human dose-finding trial has established what amount is effective or safe.
A 2025 narrative review of BPC-157 in Current Reviews in Musculoskeletal Medicine concluded that "human data are extremely limited," that only about three small pilot studies have ever examined the peptide in people, and that BPC-157 "should be considered investigational." Critically, those few human studies used intraarticular (into-a-joint) injection and intravenous administration — none used a nasal spray. So even the thin sliver of human dosing context that exists does not apply to the intranasal route at all.
Any milligram-per-spray or "X sprays per day" numbers circulating on vendor pages and forums are anecdotal and unvalidated. They are not derived from a clinical trial, they have not been tested for safety, and they cannot be relied upon. A real dose is something a regulator approves and a clinician prescribes — neither has happened here.
It is also worth understanding what an approved nasal spray actually involves, because it shows how much is missing here. A legitimate nasal product is not just a liquid in a bottle: the device is engineered to deliver a consistent, measured amount with each actuation, the concentration is fixed and verified, and the per-spray dose has been studied in people. A "research" BPC-157 spray has none of that — no validated delivery device, no verified concentration, and no human study of how much actually reaches the tissue per spray. "Two sprays" of an unstandardised product is not a dose in any meaningful sense, because the amount delivered is itself unknown and inconsistent.
What's the evidence for the nasal route specifically?
Essentially none in humans. This is the single most important point on this page. The body of BPC-157 research is overwhelmingly preclinical — rats, mice, and other animals — and even within that animal work, dedicated studies of intranasal delivery are sparse. There is no published human clinical trial evaluating a BPC-157 nasal spray for any purpose, including the "cognitive" and "neurological" benefits it is marketed for. A US Department of Defense supplement-safety resource reaches the same conclusion in plain terms: there is "little to no reliable scientific evidence" to support the safety or effectiveness of BPC-157 in humans.
Even the small amount of human dosing context that exists does not apply to the nose. The three human pilot studies a 2025 review identified used intraarticular (into-a-joint) injection and intravenous administration — not a spray. So the few people who have ever received BPC-157 in a study setting did not receive it nasally, which means there is no human starting point for an intranasal "dose" to be anchored to.
It is worth separating the chemistry from the claim. The reason BPC-157 became a research curiosity is its reported stability in human gastric juice, which is why oral and injected (parenteral) routes are the ones described in the literature. Reviews describing that stability discuss oral and parenteral administration — not nasal spray. "A peptide is stable in a test tube" and "spraying it up the nose produces a measurable benefit in a person" are two completely different statements, and only the first has any support.
| Source | Route(s) it covered | Evidence for the nasal route |
|---|---|---|
| McGuire 2025 review (humans) | Intraarticular + intravenous; ~3 pilot studies | None — no nasal route in the human data |
| He 2022 PK (rats & dogs) | Intravenous + intramuscular only | None — intranasal not studied |
| Sikiric 2011 review | Oral + parenteral (injected) | None — not intranasal |
| OPSS / U.S. DoD | Notes products sold by mouth/injection/nasal spray | "Little to no reliable" human evidence |
Does the "nose-to-brain" claim hold up?
The whole pitch for a BPC-157 nasal spray rests on one idea: that the nose offers a shortcut to the brain, letting the peptide bypass the bloodstream and deliver "cognitive" or "neurological" effects an injection supposedly cannot. It is worth taking that idea seriously enough to see where it breaks down.
It is true that intranasal delivery is a real and actively researched field for some medicines — a few drugs do use the nose-to-brain pathway. But "intranasal delivery can work for some molecules" is not the same as "it works for this molecule." Whether a given peptide actually crosses the nasal lining, survives, and reaches the brain in a meaningful amount depends entirely on its specific size, charge, and chemistry, and has to be demonstrated — not assumed. For BPC-157 specifically, that demonstration does not exist: there is no published human study showing that a nasal dose reaches the brain, produces a measurable cognitive effect, or does anything at all by that route.
So the "nose-to-brain" framing is a plausible-sounding mechanism borrowed from other drugs and applied to BPC-157 without the evidence that would make it more than a marketing theory. A believable story about how something could work is not proof that it does — and on this specific question, for this specific peptide and route, the proof is simply absent.
How long does BPC-157 last in the body?
The pharmacokinetic data that does exist further undercuts the nasal pitch. A 2022 study in rats and dogs measured how injected BPC-157 behaves in the body and found a very short elimination half-life — under roughly 30 minutes — using intravenous and intramuscular dosing. The same study reported that absolute bioavailability after intramuscular injection was about 14-19% in rats and 45-51% in dogs, and that the peptide was rapidly broken down into smaller fragments and amino acids.
Crucially, that study did not test intranasal administration at all, and it was done in animals, not people. There is no published human pharmacokinetic profile for BPC-157 by any route. So for a nasal spray, the questions that actually matter — how much of a spray is absorbed across the nasal lining, whether any of it reaches the brain in a meaningful amount, how long it stays, and what an effective or a dangerous amount would be — are all genuinely unanswered. A short half-life in an injected rat tells you nothing reliable about a spray in a human nose.
Why 'research' nasal sprays are a quality and safety unknown
Because BPC-157 is unapproved, the nasal sprays sold online are not manufactured, tested, or released as medicines. They are research-grade products, typically labeled "not for human consumption." That label is not a formality — it means no one has verified what is actually in the bottle. Identity (is it really BPC-157?), peptide purity, the true concentration, sterility, and endotoxin levels are not guaranteed, because nothing requires them to be.
For a nasal spray this matters in a specific way. The nasal lining is a mucous membrane that absorbs what it is exposed to, and a spray bottle is used repeatedly over days or weeks. A product with the wrong concentration, a contaminant, or a stability problem is being applied directly to that membrane each time. The FDA has cautioned about compounded products containing BPC-157 specifically because of "safety risks and potential contamination with other substances." A research-use-only spray sits even further outside any quality system than a compounded preparation.
The nasal route adds its own specific concerns on top of that. The lining inside the nose is delicate and richly supplied with blood vessels, and it sits close to the sinuses and, anatomically, not far from the brain. Applying an unstandardised, non-sterile liquid to it repeatedly raises real possibilities — local irritation, inflammation, or a sinus or nasal infection from a contaminated product — that simply have not been studied for any BPC-157 spray. These are not exotic risks; they are the ordinary risks of putting an unregulated substance onto a sensitive mucous membrane day after day.
There is also no human safety data to fall back on. The handful of small human studies that exist (using injection, not a spray) reported no serious adverse events, but "no problems seen in a few tiny, short studies of a different route" is not a safety profile. The long-term effects of repeated intranasal BPC-157, and the theoretical concern raised for any pro-angiogenic agent — whether it could feed abnormal tissue growth — have not been studied in people at all.
Who to actually ask
The right place for any question about whether, or how, to use an unapproved compound is a licensed clinician — not a vendor, a forum, or a page like this one. A qualified physician can weigh the complete absence of human evidence for the nasal route, the regulatory status, the anti-doping implications, and a person's individual medical picture in a way no website can.
That anti-doping point is concrete and not a gray area: BPC-157 is on the World Anti-Doping Agency Prohibited List under category S0, "Non-Approved Substances," meaning it is banned at all times, in and out of competition. Any athlete in a tested sport faces a real sanctioning risk regardless of whether the product is a spray, an injection, or a capsule. A clinician or anti-doping resource can confirm exactly what that means for a given situation.
The honest bottom line is the same one the published reviews reach: BPC-157 is investigational, the nasal route specifically has essentially no human evidence, and there is no established dose to give. Anyone considering it should treat it as the open question it is and bring it to a professional who can give individualized, accountable guidance.
Tracking a clinician-supervised protocol on PeptidePanel
PeptidePanel does not sell, source, supply, prescribe, or endorse BPC-157, nasal sprays, or any compound, and nothing here is medical advice. BPC-157 is unapproved, its intranasal use is unproven in humans, and no standard dose exists in any regulatory document.
PeptidePanel is a neutral record-keeping tool. If a licensed clinician is supervising an experimental protocol, the discipline of documenting it — the timeline, any relevant bloodwork the clinician is watching, and any effects observed — is what gives a clearer longitudinal picture over time. The value is in the organized record, not in PeptidePanel endorsing, supplying, or validating anything. The decision to use any investigational compound belongs with a licensed physician who understands the risks.